Mab immunotherapies for myeloid leukemia patients with germline or somatic RUNX1 mutations.

用于具有种系或体细胞 RUNX1 突变的骨髓性白血病患者的 Mab 免疫疗法。

• 批准号: nhmrc : GNT1145278
• 负责人: A/Pr Ian Lewis
• 金额: $ 76.7万
• 依托单位: University of South Australia
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2018
• 资助国家: 澳大利亚
• 起止时间: 2018-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/mab-immunotherapies-myeloid-runx1-mutations/1348681
• 关键词: Mab; immunotherapies; myeloid; leukemia; patients

This proposal presents preliminary evidence and proposes to confirm that 2 cell surface molecules, CD11a (ITGAL) and IL3RA (CD123) are direct (probably repression) targets of RUNX1 in HSCs, and are dysregulated in RUNX1 mutated AML. Monoclonal antibody therapies that target these two surface molecules have already passed different clinical trial phases for different diseases. We plan to show these antibodies are effective in RUNX1 positive AML in preclinical models and then clinical trials.

该提案提供了初步证据，并建议确认2种细胞表面分子，CD11a（ITGAL）和IL3RA（CD123）是HSC中RUNX1的直接（可能是抑制）靶点，并且在RUNX1突变的AML中失调。针对这两种表面分子的单克隆抗体疗法已经通过了针对不同疾病的不同临床试验阶段。我们计划在临床前模型和临床试验中证明这些抗体对RUNX1阳性AML有效。